Home > Cardiology > EHRA 2022 > Other Topics > Updates on anti-arrhythmic agents

Updates on anti-arrhythmic agents

Presented By
Prof. John Camm, St George’s University of London, UK
Conference
EHRA 2022
Doi
https://doi.org/10.55788/0ff7d6b4
The INSTANT study showed that oral inhalation of flecainide restored sinus rhythm in patients with recent-onset atrial fibrillation. In the NODE-301 trial, etripamil nasal spray showed to significantly improve paroxysmal supraventricular tachycardia-related symptoms. Small-conductance calcium-activated potassium channel inhibitors showed to delay the cardiac action potential and seem to be atrial selective. Sulcardine reduced the J-Tp interval, a feature only seen for this agent. The GENETIC-AF trial showed a preventive effect of bucindolol on new-onset atrial fibrillation (AF), and, finally, botulinum toxin A delayed postoperative AF after injection. Prof. John Camm (St George’s University of London, UK) discussed the latest evidence concerning the development of novel anti-arrhythmic drugs (AAD) and corresponding administration methods [1]. Inhaled flecainide for AF is currently being tested in the phase 2 INSTANT study (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on